Precision Biosciences Inc
Precision Biosciences Inc (DTIL) Covered Calls
Precision Biosciences Inc trades in the Biotechnology industry with an IV Rank of 65.08%, average versus the past year. DTIL's highest covered call setup is the $10.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 32.28% out of the money with 63 days to expiration, a 35.58% return until expiration, and a 206.15% theoretical annualized return. Across the setups shown, annualized returns run from 206.15% to 206.15% at strikes between $10.00 and $10.00, with 63 days to expiration, as of Nov 13, 2026.
Read more
Running DTIL covered calls helps you generate income from Precision Biosciences Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best DTIL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If DTIL stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling DTIL covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given DTIL covered call is worth writing.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
| 2027-01-15 | 63 | 10.00 | 32.28 | 0.25 | 1.35 | 269.00 | 35.58 | 206.15 | -3.31 | +0.39 | 99 | 1.10 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank65.08% Moderate
- Market cap (M$)193
- 52 weeks high-38.80%
- 52 weeks low95.75%
- Analyst recommendationStrong Buy
1.00 - Target price$29.40
297.30% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-03
- P/E—
- Future P/E—
- EPS (ttm)-1.28
- EPS growth next 5 years20.78%
As of Nov 19, 2026